Home » News » Drug Sponsors » Valeant Pharma acquires 19.9% minority equity investment in Brazilian biotech

Valeant Pharma acquires 19.9% minority equity investment in Brazilian biotech

Tuesday, March 13, 2012

Valeant Pharmaceuticals International has acquired a 19.9% minority equity investment in Pele Nova Biotecnologia, a Brazilian research company focused on tissue regeneration. 

In return for the ownership, for which Valeant paid less than $10 million, Valeant will have representation on Pele Nova’s board of directors, a reduced royalty rate for Regederm, rights to all future products in Brazil and the first right of refusal for global product rights. 

Regederm, a biologic wound healing product, was recently approved in Brazil and is expected to launch in April.

“We are excited about another unique opportunity in Brazil,” said J. Michael Pearson, chairman and CEO of Valeant. “Our investment in Pele Nova follows the successful approval for Regederm, originally licensed by Instituto Terapeutico Delta, a company that was acquired by Valeant in 2010, and is expected to provide us with a potential pipeline of biologic compounds in the future.” 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!